dc.contributor.author | Grimmett, C | |
dc.contributor.author | Haviland, J | |
dc.contributor.author | Winter, J | |
dc.contributor.author | Calman, L | |
dc.contributor.author | Din, A | |
dc.contributor.author | Richardson, A | |
dc.contributor.author | Smith, PWF | |
dc.contributor.author | Foster, C | |
dc.date.accessioned | 2017-08-29T10:18:25Z | |
dc.date.issued | 2017-10-01 | |
dc.identifier.citation | Journal of cancer survivorship : research and practice, 2017, 11 (5), pp. 634 - 642 | |
dc.identifier.issn | 1932-2259 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/794 | |
dc.identifier.eissn | 1932-2267 | |
dc.identifier.doi | 10.1007/s11764-017-0636-x | |
dc.description.abstract | PURPOSE: There is a growing emphasis on self-management of cancer aftercare. Little is known about patient's self-efficacy (confidence) to manage illness-related problems and how this changes over time. This paper describes the patterns of self-efficacy for managing illness-related problems amongst colorectal cancer patients in the 2 years following diagnosis. METHODS: In this prospective cohort study, questionnaires were administered at baseline (pre-surgery), 3, 9, 15 and 24 months to 872 colorectal cancer patients. Self-efficacy (confidence to manage illness-related problems), anxiety, social support, affect, socio-demographics, physical symptoms and clinical and treatment characteristics were assessed. Group-based trajectory analysis identified trajectories of self-efficacy up to 24 months and predictors. RESULTS: Four trajectories of self-efficacy were identified: group 1 (very confident) 16.0% (95% confidence interval (CI) 10.7-21.3%), group 2 (confident) 45.6% (95% CI 40.3-51.0%), group 3 (moderately confident) 29.5% (95% CI 25.1-33.8%) and group 4 (low confidence) 8.9% (95% CI 6.4-11.4%). Greater deprivation, domestic status, more co-morbidities, worse fatigue and pain, lower positivity and greater negativity were significantly associated with lower self-efficacy. There was an increase in mean scores for self-efficacy over time for the whole sample, but this did not reach the cut-off for minimally important differences. At 2 years, the lowest level of confidence to manage was for symptoms or health problems. CONCLUSION: Around 40% of patients had suboptimal levels of confidence to manage illness-related problems with little change from the time of diagnosis across the four groups. IMPLICATIONS FOR CANCER SURVIVORS: Screening for self-efficacy at diagnosis would enable targeted, early intervention which could in turn enhance health-related quality of life. | |
dc.format | Print-Electronic | |
dc.format.extent | 634 - 642 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Colorectal Neoplasms | |
dc.subject | Aftercare | |
dc.subject | Prospective Studies | |
dc.subject | Self Efficacy | |
dc.subject | Time Factors | |
dc.subject | Quality of Life | |
dc.subject | Middle Aged | |
dc.subject | Survivors | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Self-Management | |
dc.title | Colorectal cancer patient's self-efficacy for managing illness-related problems in the first 2 years after diagnosis, results from the ColoREctal Well-being (CREW) study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-08-01 | |
rioxxterms.versionofrecord | 10.1007/s11764-017-0636-x | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-10 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of cancer survivorship : research and practice | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Haviland, Joanne | |